Theriva Biologics
TOVX
27 hedge funds and large institutions have $3.91M invested in Theriva Biologics in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 7 closing their positions.
0% more funds holding
Funds holding: 27 → 27 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
32% less capital invested
Capital invested by funds: $5.8M → $3.91M (-$1.88M)
80% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$271K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$57.6K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.9K |
| 4 |
Two Sigma Advisers
New York
|
+$19.3K |
| 5 |
SCM
Sterneck Capital Management
Kansas City,
Missouri
|
+$14.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
-$484K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$331K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$303K |
| 4 |
BlackRock
New York
|
-$270K |
| 5 |
VF
Virtu Financial
New York
|
-$124K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TI
26
tru Independence
Portland,
Oregon
| – | -$30K | -240 | Closed |
|
27
Charles Schwab
San Francisco,
California
| – | -$36K | -209 | Closed |
|
|
NA
28
NewEdge Advisors
New Orleans,
Louisiana
| – | -$10K | -57 | Closed |
|
|
CWP
29
Concord Wealth Partners
Abingdon,
Virginia
| – | -$1K | -4 | Closed |
|
TOVX Hedge Fund Activity: Q2 2021 in Review
27 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2021, worth a combined $3.91M — down 32% from $5.8M a quarter earlier.
Fund positioning in TOVX was balanced in Q2 2021: 7 funds opened new positions, 7 closed out, 2 added to existing stakes and 10 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $271K. The largest seller was MSD Partners, cutting an estimated $484K.
- 27 institutional investors held Theriva Biologics (TOVX) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $3.91M of Theriva Biologics stock for Q2 2021, down 32% quarter-over-quarter.
- 7 funds opened new Theriva Biologics positions in Q2 2021 and 7 closed out, a net change of 0 holders.
- The largest Theriva Biologics buyer in Q2 2021 was State Street, an estimated $271K added.
- The largest Theriva Biologics seller in Q2 2021 was MSD Partners, an estimated $484K sold.
Based on aggregated 13F filings for Q2 2021.